Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.23 (beta-galactosidase)
 14,648 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. myo-Inositol was galactosylated by UDP-galactose in the presence of alpha-lactalbumin plus rat mammary Golgi membranes enriched in galactosyltransferase (EC 2.4.1.22). 2. The isolated product migrated on GLC as two peaks of material, apparently identical to galactinol (galactosylinositol) isolated from rat milk. 3. These findings make it likely that in vivo lactose synthetase is responsible for converting inositol into galactinol within the Golgi lumen. 4. This is consistent with the ability of inositol to penetrate the Golgi membrane in vitro, and renders less likely a previously proposed role of beta-galactosidase (EC 3.2.1.23) in mammary galactinol synthesis.
 ...
PMID:Biosynthesis of galactinol by lactose synthetase. 680 5

A high galactosyltransferase activity with lactotriaosylceramide as acceptor has been found in human serums. The reaction requires UDP-galactose, Mn2+, and Triton X-100. It has a pH optimum of 6.0 and a Km for lactotriaosylceramide of 0.66 mM. On the basis of methylation analysis and susceptibility towards beta-galactosidase the reaction product has been identified as neolactotetraosylceramide. Lactotetraosylceramide formation was not observed. Evidence is presented that the serum enzymic activity can be attributed to N-acetyllactosamine synthase (EC 2.4.1.90). The beta 1 leads to 4-galactosyltransferase activities with lactotriaosylceramide as acceptor have been determined in different human sera. The activity is independent of ABO, p and Rh blood-group status. The enzyme is within a normal range in serums of cancer patients.
 ...
PMID:Enzymatic synthesis of neolactotetraosylceramide by the N-acetyllactosamine synthase of human serum. 681 Dec 67

Beta 1,4 galactosyl- and alpha 2,6 sialyltransferase (gal-T EC 2.4.1.22 and sialyl-T EC 2.4.99.1) sequentially elongate and terminate complex N-glycan chains of glycoproteins. Both enzymes reside in trans Golgi cisternae; their ultrastructural relationship, however, is unknown. To delineate their respective Golgi compartment(s) we conducted a double label immunofluorescent study by conventional and confocal laser scanning microscopy in HepG2, HeLa, and other cells in presence of Golgi-disturbing agents. Polyclonal, peptide-specific antibodies to human sialyl-T expressed as a beta-galactosidase-sialyl-T fusion protein in E. coli were developed and applied together with mABs to human milk gal-T. In untreated HepG2 and HeLa cells Golgi morphology identified by immunofluorescent labeling of sialyl-T and gal-T, respectively, was nearly identical. Treatment of cells with brefeldin A (BFA) led to rapid and coordinated disappearance of immunostaining of both enzymes; after BFA washout, vesicular structures reappeared which first stained for gal-T followed by sialyl-T; in the reassembled Golgi apparatus sialyl-T and gal-T were co-localized again. In contrast, monensin treatment produced a reversible swelling and scattering of gal-T positive Golgi elements while sialyl-T positive structures showed little change. Treatment with nocodazole led to dispersal of Golgi elements in which gal-T and sialyl-T remained co-localized. Treatment with chloroquine affected Golgi structures less than monensin and led to condensation of gal-T positive and to slight enlargement of sialyl-T positive structures. Sequential recovery from BFA of gal-T and sialyl-T and their segregation by monensin suggest that these enzymes are targeted to different Golgi subcompartments.
 ...
PMID:Double immunofluorescent staining of alpha 2,6 sialyltransferase and beta 1,4 galactosyltransferase in monensin-treated cells: evidence for different Golgi compartments? 769 43